查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012794

抗病毒藥物市場：2026-2032年全球市場預測（依適應症、藥物類別、給藥途徑、最終用戶和分銷管道分類）

Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗病毒藥物市場價值將達到 628.1 億美元，到 2026 年將成長至 659.2 億美元，到 2032 年將達到 1008.3 億美元，複合年成長率為 6.99%。

主要市場統計數據
基準年 2025 628.1億美元
預計年份：2026年 659.2億美元
預測年份 2032 1008.3億美元
複合年成長率 (%) 6.99%

為策略領導者提供當前抗病毒治療趨勢的簡明概述，整合了科學進步、臨床挑戰和系統性影響。

抗病毒藥物領域正處於一個轉折點，治療方法創新、醫療服務模式轉變以及不斷變化的監管預期相互交織，重塑研發和商業性模式。本執行摘要整合了適應症、藥物類別和分銷管道中最關鍵的趨勢，並將其轉化為臨床團隊、商業領導者和供應鏈負責人所需的策略洞察。其目標是將複雜的跨學科數據以可操作的方式呈現給那些必須在短期營運重點和長期研發規劃之間取得平衡的領導者。

對科學、監管和交付方法的創新融合進行詳細分析，這些創新正在從根本上重塑抗病毒藥物的開發和商業化途徑。

抗病毒療法的研發和應用正經歷著許多變革，這些變革正在改變競爭格局和臨床環境。生物製藥和核酸技術正從概念驗證（PoC）階段邁向成熟的治療策略，推動著旨在延長藥效持續時間、提高遵守用藥以及開展靶向性、基於機制干預的治療項目。同時，診斷和治療技術的融合使得早期檢測和「檢測即治療」模式成為可能，並影響臨床試驗設計和打入市場策略。

對 2025 年美國關稅變化將給採購帶來的直接壓力以及這些變化將為供應鏈韌性和製造本地化創造的策略獎勵進行全面評估。

美國2025年實施的關稅調整的累積影響，正對參與抗病毒治療的機構在採購、生產和臨床運營等各個領域造成多方面的壓力。關鍵化學中間體和某些成品藥的進口關稅增加了依賴全球供應鏈的企業的接收成本，迫使採購團隊重新思考籌資策略，並考慮將生產外包或選擇替代供應商以維持供應的連續性。這種供應商多元化的轉變通常需要大量的前置作業時間和資金投入，以選擇替代的生產合作夥伴並確保符合監管品質標準。

詳細的細分洞察涵蓋適應症、治療領域、給藥途徑、分銷管道和終端用戶趨勢，從而推動差異化策略。

基於適應症的細分揭示了乙型肝炎、丙型肝炎、單純皰疹病毒、愛滋病毒、流感和呼吸道融合細胞病毒（RSV）在臨床需求和商業策略方面的不同路徑。乙型肝炎計畫日益重視持續性病毒抑制和功能性治癒策略，這需要長期安全性和生物標記的開發。同時，丙型肝炎計畫則著重於簡化治療方法和支持廣泛病例發現的獲取模式。單純皰疹的管理仍然著重於控制和預防高風險族群的感染。愛滋病毒研究在探索長效製劑和以治癒為導向的治療方法的同時，也沿用了現有的慢性病管理模式。流感和呼吸道融合細胞病毒（RSV）計畫優先考慮季節性治療方法和快速診斷，以最佳化治療和預防的時機。

一項策略性區域分析，重點闡述了美洲、歐洲、中東和非洲以及亞太地區的監管、臨床和製造因素如何影響實際選擇。

區域趨勢對整個抗病毒藥物領域的研發重點、製造地選擇和商業化策略的發展至關重要。在美洲，完善的研究基礎設施和廣泛的臨床試驗網路為快速轉化研究提供了支持，而政策辯論和支付方框架則影響定價策略和准入模式。此外，美洲作為長效製劑和先進治療方法的主要市場發揮關鍵作用，並擁有能夠處理複雜的基於價值的合約和上市後證據收集的醫療保健系統。

從公司層級切實觀點創新、製造策略和夥伴關係模式，這些正在抗病毒藥物的開發和商業化中創造競爭優勢。

抗病毒療法領域的企業策略正趨向於幾個高影響力優先事項：推動差異化治療方法的研發、確保強大的生產能力以及在整個生態系統中建立合作夥伴關係。主要企業正在平衡有針對性的授權和共同開發契約，以加速新型機制的獲取，同時推動內部創新，並管控技術風險。對能夠實現模組化適應多種病毒標靶的平台技術的投資，正在加速從藥物發現到臨床候選藥物的轉化。企業也越來越重視那些具有明確路徑、能夠提高遵守用藥並減少密集監控需求的資產。

針對抗病毒藥物領域，提出具體且高度優先的建議，以促進研發、生產韌性、與支付者合作以及商業性實施，從而推動抗病毒藥物領域的持續成功。

產業領導企業應優先採取一系列切實可行的措施，使研發選擇與商業性執行和供應鏈韌性保持一致。首先，應加快對長效和標靶給藥方式的投資，以顯著提高用藥依從性並減輕醫療系統的負擔，同時制定完善的真實世界數據收集計劃，以支持醫保報銷，並配合臨床開發計劃。其次，應透過選擇區域合作夥伴和靈活的契約製造來實現製造地的多元化，並納入情境規劃，以應對關稅波動和原料短缺，從而最大限度地降低臨床試驗和商業供應的風險。

對多方面的調查方法進行透明的解釋，這些方法結合了專家訪談、監管和科學審查以及情境分析，以檢驗實際見解。

本執行摘要的研究採用多方面方法，交叉引用專家訪談、二手文獻、監管申報文件和技術資料來源，以確保提供全面且檢驗的見解。一手資訊來源包括對臨床研究人員、供應鏈經理、監管專家和商業領域領導者的結構化訪談，從而提供關於營運挑戰、臨床重點和支付方期望的實地觀點。二手研究涵蓋同儕審查文獻、臨床試驗註冊資料、專利趨勢和已發布的監管決策，以捕捉科學趨勢和開發平臺。

最終整合關鍵策略重點，將科學預期轉化為抗病毒治療領域堅實的臨床和商業性成功。

總之，抗病毒療法正進入一個技術快速發展、供應鏈日益複雜、市場准入要求不斷變化的時期。科學進步為透過長效藥物和標靶治療方法改善患者預後提供了明確的途徑，但其成功實用化需要靈活的生產策略、整合的診斷方法以及與支付方的有效溝通。區域監管預期與關稅驅動的供應動態之間的交互作用凸顯了在地化實施和完善的緊急時應對計畫的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗病毒藥物市場：依適應症分類

  • B型肝炎
  • C型肝炎
  • 單純皰疹
  • HIV
  • 流感
  • 呼吸道融合細胞病毒

第9章：抗病毒藥物市場：依藥物類別分類

  • 融合抑制劑
  • 整合酶抑制劑
  • 非核苷類逆轉錄酶抑制劑
  • 核苷類似物
  • 蛋白酶抑制劑

第10章：抗病毒藥物市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服
  • 外用

第11章：抗病毒藥物市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院
  • 長期照護機構

第12章 抗病毒藥物市場：依分銷管道分類

  • 診所
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 抗病毒藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗病毒藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗病毒藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗病毒藥物市場

第17章：中國抗病毒藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8289

The Antiviral Drugs Market was valued at USD 62.81 billion in 2025 and is projected to grow to USD 65.92 billion in 2026, with a CAGR of 6.99%, reaching USD 100.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 62.81 billion
Estimated Year [2026] USD 65.92 billion
Forecast Year [2032] USD 100.83 billion
CAGR (%) 6.99%

Concise orientation to the current antiviral therapeutics landscape that synthesizes scientific advances, clinical pressures, and system implications for strategic leaders

The antiviral drugs landscape is at an inflection point where therapeutic innovation, shifting care delivery models, and evolving regulatory expectations intersect to reshape research, development, and commercial approaches. This executive summary synthesizes the most consequential developments across indications, drug classes, and distribution channels, and it translates those developments into strategic implications for clinical teams, commercial leaders, and supply chain executives. The goal is to present an actionable condensation of complex, cross-disciplinary data for leaders who must balance near-term operational priorities with longer-term R&D pathways.

To ensure relevance across stakeholder groups, the analysis foregrounds clinical unmet needs, technology enablers, and system pressures that are redefining how antiviral therapies are developed and delivered. The narrative integrates scientific trajectories-such as advances in antiviral modalities and diagnostics-with practical considerations including procurement practices, payer engagement, and the operationalization of outpatient care. Throughout, emphasis is placed on decisions that influence patient access, therapeutic value, and resilience against supply disruptions, providing a concise yet nuanced orientation for planning and investment decisions.

Detailed analysis of the converging scientific, regulatory, and delivery innovations that are fundamentally reshaping development and commercialization pathways for antivirals

A number of transformative shifts are altering the competitive and clinical contours of antiviral therapy development and delivery. Biologic modalities and nucleic acid technologies have moved from proof-of-concept stages into validated therapeutic strategies, fueling programs that aim to deliver longer duration of effect, improved adherence, and targeted mechanism-based interventions. Concurrently, diagnostics are converging with therapeutics to enable earlier detection and test-and-treat paradigms, which in turn influence clinical trial design and commercial access strategies.

Regulatory pathways have adjusted to accommodate accelerated development in high-need areas, and payers are increasingly tying reimbursement to demonstrable real-world outcomes and health economic value. Digital health tools are being integrated into patient monitoring and adherence programs, supporting decentralized care models and shifting utilization away from inpatient settings when clinically appropriate. Manufacturing innovation, including flexible biologics capacity and modular production techniques, is reducing lead times and enabling regionalized supply chains. These shifts collectively create a landscape in which agility, cross-sector partnerships, and rapid evidence generation determine who can translate scientific promise into durable clinical and commercial success.

Comprehensive assessment of how the 2025 United States tariff changes create immediate procurement pressures and strategic incentives for supply chain resilience and manufacturing localization

The cumulative effect of the United States tariff adjustments enacted in 2025 introduces multifaceted pressures across procurement, manufacturing, and clinical operations for organizations engaged in antiviral therapeutics. Import duties on key chemical intermediates and selected finished pharmaceuticals have increased landed costs for firms that rely on global supply networks, prompting procurement teams to reassess sourcing strategies and to explore nearshoring or alternate supplier qualification to maintain continuity. This reorientation toward supplier diversification often requires significant lead time and capital investment to qualify alternate manufacturing partners and to ensure compliance with regulatory quality standards.

Clinics and hospital systems face increased variability in procurement pricing, which in turn affects purchasing cycles and inventory policies; some institutions are extending inventory buffers while others are negotiating longer term purchasing agreements to mitigate volatility. For developers, tariff-driven cost pressures can change the calculus for where and how manufacturing scale-up is executed, potentially favoring regional production hubs that reduce exposure to cross-border duties despite higher local operating costs. The tariffs also influence the dynamics of contract manufacturing organizations, as increased demand for domestic or qualified regional capacity creates competitive pressure on timelines and pricing.

Policy responses and private sector strategies are emerging to offset impacts, including targeted supply agreements, increased vertical integration, and strategic stockpiling for critical active pharmaceutical ingredients. These adjustments have downstream effects on the speed of clinical trial material provisioning, the cost base for pricing negotiations with payers and procurers, and the prioritization of therapeutic pipelines that require fewer complex inputs. In aggregate, the tariff environment accelerates a strategic shift toward resilience and redundancy in supply chains while elevating the importance of cost containment through process innovation and manufacturing efficiency.

In-depth segmentation insights spanning indications, therapeutic classes, administration routes, distribution channels, and end-user dynamics driving differentiated strategies

Segmentation by indication reveals differentiated pathways of clinical need and commercial strategy across Hepatitis B, Hepatitis C, Herpes Simplex, HIV, Influenza, and Respiratory Syncytial Virus. Hepatitis B programs are increasingly focused on durable viral suppression and functional cure strategies, demanding long-term safety and biomarker development, whereas Hepatitis C efforts emphasize simplified regimens and access models that support broad case finding. Herpes Simplex management remains concentrated on episodic control and prophylaxis for high-risk populations, while HIV research balances long-acting formulations and cure-directed approaches alongside established chronic care models. Influenza and Respiratory Syncytial Virus programs prioritize seasonally responsive therapies and rapid diagnostics to optimize timing of treatment and prophylaxis.

When viewed by drug class, priorities vary between Fusion Inhibitors, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Analogues, and Protease Inhibitors. Integrase and fusion inhibitors are attracting interest for novel resistance profiles and tolerability advantages, while nucleoside analogues and protease inhibitors remain foundational for established regimens that require careful lifecycle management. Non-Nucleoside Reverse Transcriptase Inhibitors continue to be evaluated for improved safety profiles and combination strategies that enhance durability and adherence.

Routes of administration, spanning inhalation, injectable, oral, and topical, shape patient adherence, distribution logistics, and clinical setting. Oral therapies remain central for outpatient management and chronic disease maintenance, injectables and long-acting formulations support adherence and reduce clinic visit frequency, inhalation therapeutics offer targeted pulmonary exposure for respiratory viruses, and topical formulations maintain relevance for mucocutaneous infections where localized delivery improves tolerability.

Distribution channel dynamics across clinics, hospital pharmacies, online pharmacies, and retail pharmacies influence access, reimbursement pathways, and point-of-care decisioning. Clinics and hospital pharmacies often handle complex regimens and parenteral products supported by institutional procurement processes, while online and retail pharmacies expand reach and convenience for oral and topical therapies. Finally, end user segmentation that includes clinics, home care, hospitals, and long term care facilities highlights the importance of care setting in therapeutic choice, with home care and outpatient clinics driving demand for user-friendly formulations and simplified monitoring protocols, and hospitals and long term care facilities requiring robust supply and administration workflows for complex regimens.

Strategic regional considerations highlighting how distinct regulatory, clinical, and manufacturing factors in the Americas, Europe Middle East & Africa, and Asia-Pacific shape execution choices

Regional dynamics are central to shaping R&D priorities, manufacturing placement, and commercialization approaches across the antiviral landscape. In the Americas, established research infrastructure and widespread clinical trial networks support rapid translational efforts, while policy debates and payer frameworks influence pricing strategies and access models. The Americas also function as a key market for long-acting and advanced modality launches, with healthcare systems that can absorb complex value-based contracting and post-launch evidence collection.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with varied reimbursement landscapes. European regulatory frameworks favor robust comparative effectiveness and health economic evidence, motivating manufacturers to invest in real-world data generation and payer engagement early in development. The Middle East & Africa region presents distinct access challenges and opportunities for public-private partnerships focused on manufacturing capacity building and distribution networks that reach underserved populations.

Asia-Pacific is a diverse region that combines rapidly expanding R&D investment, large patient populations with significant unmet needs, and emerging manufacturing prowess. Several economies within Asia-Pacific are investing heavily in both small molecule and biologics manufacturing, and favorable policy incentives are accelerating clinical development throughput. Commercial strategies in the region must reconcile heterogenous payer systems, variable patient affordability, and the increasing role of digital channels for patient engagement and distribution. Across all regions, successful programs are those that tailor evidence generation, supply chain design, and commercial models to local regulatory expectations and care delivery realities.

Practical company-level perspectives on innovation, manufacturing strategy, and partnership models that are driving competitive advantage in antiviral development and commercialization

Company strategies in antiviral therapeutics are converging on a few high-impact priorities: advancing differentiated modalities, securing resilient manufacturing capacity, and forging collaborative partnerships across the ecosystem. Leading developers are balancing in-house innovation with targeted licensing and co-development agreements that accelerate access to novel mechanisms while managing technical risk. Investment in platform technologies that enable modular adaptation across viral targets is enabling faster transition from discovery to clinical candidate, and companies are increasingly prioritizing assets with clear pathways to improved adherence or reduced need for intensive monitoring.

Operationally, firms are bolstering supply chain integration and expanding capacity through selective vertical moves or strategic manufacturing partnerships to reduce exposure to cross-border cost shocks. Commercially, organizations are experimenting with value-based contracting and payer partnerships that align long-term outcomes with reimbursement structures, while specialist commercialization teams focus on differentiated channels such as hospital formularies and specialty pharmacies. Smaller biotech firms are leveraging nimble development processes and focused proof-of-concept studies to attract partnerships, while larger multinational pharmaceutical companies provide scale, regulatory expertise, and access to global distribution networks. Across company types, success increasingly depends on the ability to translate clinical differentiation into demonstrable patient and system value and to operationalize that value across complex care pathways.

Concrete and prioritized recommendations for R&D prioritization, manufacturing resilience, payer engagement, and commercial execution to drive durable success in antivirals

Industry leaders should prioritize a suite of actionable measures that align R&D choices with commercial execution and supply chain resilience. First, accelerate investment in long-acting and targeted delivery modalities that demonstrably improve adherence and reduce system burden, pairing clinical development plans with robust plans for real-world evidence collection to support reimbursement. Second, diversify manufacturing footprints by qualifying regional partners and flexible contract manufacturers, and incorporate scenario planning for tariff-driven disruptions and input scarcity to minimize risks to clinical trials and commercial supply.

Third, design launch strategies that integrate diagnostics and telehealth pathways, enabling rapid identification of treatment-eligible patients and reducing barriers to initiation. Fourth, engage payers early to define evidence requirements and to explore outcome-based reimbursement structures that share risk and reward. Fifth, cultivate strategic alliances that pair platform technologies with commercialization expertise, whether through co-development, licensing, or targeted acquisitions that fill capability gaps. Sixth, invest in digital and patient support programs that improve adherence, collect outcome data, and reduce the total cost of care. Finally, embed sustainability into procurement and manufacturing decisions to reduce exposure to geopolitical and tariff pressures while meeting growing stakeholder expectations for resilient and responsible operations.

Transparent description of the multi-method research approach combining expert interviews, regulatory and scientific review, and scenario analysis to validate actionable insights

The research underpinning this executive summary draws on a multi-method approach that triangulates primary expert interviews, secondary literature, regulatory filings, and technical data sources to ensure comprehensive and validated insights. Primary inputs included structured interviews with clinical investigators, supply chain managers, regulatory experts, and commercial leaders, providing ground-level perspectives on operational challenges, clinical priorities, and payer expectations. Secondary review encompassed peer-reviewed literature, clinical trial registries, patent landscapes, and public regulatory decisions to map scientific trends and development pipelines.

Analytical methods included qualitative thematic synthesis to identify recurrent strategic themes, comparative policy analysis to discern regional regulatory implications, and scenario planning to evaluate supply chain and tariff impacts. Quality assurance was maintained through cross-validation of interview findings with document review and by presenting interim themes to an independent panel of subject matter experts for feedback. The methodology acknowledges limitations inherent to horizon scanning and expert elicitation, including potential sampling bias in interview subjects and the rapidly evolving nature of clinical research; these limitations were mitigated through diverse stakeholder engagement and repeated validation cycles. The resulting insights prioritize robustness and practical relevance for decision makers seeking to align near-term operational imperatives with longer-term strategic objectives.

Final synthesis of the critical strategic priorities for converting scientific promise into durable clinical and commercial success in antiviral therapeutics

In summation, antiviral therapeutics are entering a period defined by technological momentum, heightened supply chain complexity, and evolving market access requirements. Scientific advances provide clear pathways to improved patient outcomes through longer-acting agents and targeted modalities, yet successful translation depends on adaptive manufacturing strategies, integrated diagnostics, and sophisticated payer engagement. The interplay of regional regulatory expectations and tariff-driven supply dynamics underscores the importance of localized execution and robust contingency planning.

Leaders who align clinical development with pragmatic proofs of value, diversify manufacturing and procurement approaches, and invest in digital tools for adherence and evidence capture will be best positioned to convert scientific potential into accessible therapies. The recommendations contained in this summary are intended to guide immediate operational decisions while supporting longer-term investments that build durable competitive advantage. Organizations that act with both tactical responsiveness and strategic foresight can mitigate near-term disruptions and unlock sustainable growth opportunities in the evolving antiviral landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Drugs Market, by Indication

  • 8.1. Hepatitis B
  • 8.2. Hepatitis C
  • 8.3. Herpes Simplex
  • 8.4. Hiv
  • 8.5. Influenza
  • 8.6. Respiratory Syncytial Virus

9. Antiviral Drugs Market, by Drug Class

  • 9.1. Fusion Inhibitors
  • 9.2. Integrase Inhibitors
  • 9.3. Non Nucleoside Reverse Transcriptase Inhibitors
  • 9.4. Nucleoside Analogues
  • 9.5. Protease Inhibitors

10. Antiviral Drugs Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical

11. Antiviral Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Long Term Care Facilities

12. Antiviral Drugs Market, by Distribution Channel

  • 12.1. Clinics
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Antiviral Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiviral Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antiviral Drugs Market

17. China Antiviral Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. AstraZeneca plc
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim GmbH
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Cipla Limited
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Hetero Labs Limited
  • 18.16. Johnson & Johnson
  • 18.17. Merck & Co., Inc.
  • 18.18. Mylan N.V.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Roche Holding AG
  • 18.22. Sandoz International GmbH
  • 18.23. Sanofi S.A.
  • 18.24. Sun Pharmaceutical Industries Ltd.
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)